Goldman Sachs Group Inc Harvard Bioscience Inc Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 12,694 shares of HBIO stock, worth $8,251. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,694

Previous 207,646 93.89%

Holding current value

$8,251

Previous $91,000 94.51%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.4 - $0.57 $77,980 - $111,122	-194,952 Reduced 93.89%	12,694 $5,000
Q2 2025 Aug 14, 2025	BUY	$0.28 - $0.69 $17,175 - $42,325	61,341 Added 41.93%	207,646 $91,000
Q1 2025 May 09, 2025	SELL	$0.57 - $2.19 $29,126 - $111,906	-51,099 Reduced 25.89%	146,305 $83,000
Q4 2024 Feb 11, 2025	BUY	$2.02 - $2.82 $44,399 - $61,983	21,980 Added 12.53%	197,404 $416,000
Q3 2024 Nov 14, 2024	BUY	$2.64 - $3.54 $257,637 - $345,468	97,590 Added 125.38%	175,424 $471,000

Q2 2024 Aug 13, 2024	BUY	$2.77 - $4.63 $104,994 - $175,495	37,904 Added 94.93%	77,834 $221,000
Q1 2024 May 15, 2024	SELL	$4.02 - $5.39 $1,382 - $1,854	-344 Reduced 0.85%	39,930 $169,000
Q4 2023 Feb 13, 2024	BUY	$4.0 - $5.49 $39,572 - $54,312	9,893 Added 32.56%	40,274 $215,000
Q3 2023 May 14, 2024	SELL	$4.0 - $5.82 $39,572 - $57,577	-9,893 Reduced 24.56%	30,381 $130,000
Q3 2023 Nov 14, 2023	SELL	$4.0 - $5.82 $66,580 - $96,873	-16,645 Reduced 35.4%	30,381 $130,000
Q2 2023 May 14, 2024	BUY	$4.19 - $6.16 $41,631 - $61,205	9,936 Added 26.79%	47,026 $258,000
Q2 2023 Aug 14, 2023	BUY	$4.19 - $6.16 $41,631 - $61,205	9,936 Added 26.79%	47,026 $258,000
Q1 2023 May 14, 2024	BUY	$2.45 - $4.22 $59,623 - $102,697	24,336 Added 190.81%	37,090 $155,000
Q1 2023 May 11, 2023	BUY	$2.45 - $4.22 $59,623 - $102,697	24,336 Added 190.81%	37,090 $155,000
Q4 2022 May 14, 2024	SELL	$2.12 - $2.86 $51,687 - $69,729	-24,381 Reduced 65.66%	12,754 $35,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $2.86 $51,687 - $69,729	-24,381 Reduced 65.66%	12,754 $35,000
Q3 2022 May 14, 2024	SELL	$2.33 - $3.92 $60,307 - $101,461	-25,883 Reduced 41.07%	37,135 $95,000
Q3 2022 Nov 10, 2022	SELL	$2.33 - $3.92 $60,307 - $101,461	-25,883 Reduced 41.07%	37,135 $0
Q2 2022 May 14, 2024	BUY	$3.28 - $6.42 $74,600 - $146,016	22,744 Added 56.47%	63,018 $227,000
Q2 2022 Aug 15, 2022	SELL	$3.28 - $6.42 $100,755 - $197,209	-30,718 Reduced 32.77%	63,018 $227,000
Q1 2022 May 16, 2022	SELL	$5.16 - $7.14 $19,927 - $27,574	-3,862 Reduced 3.96%	93,736 $583,000
Q4 2021 Feb 14, 2022	SELL	$6.37 - $8.18 $19,129 - $24,564	-3,003 Reduced 2.99%	97,598 $688,000
Q3 2021 Nov 10, 2021	BUY	$6.98 - $8.47 $702,194 - $852,090	100,601 New	100,601 $702,000

Others Institutions Holding HBIO

# of Institutions

Shares Held

19.5M

Call Options Held

54K

Put Options Held

View Full List

About HARVARD BIOSCIENCE INC

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $27.1M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

More about HBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Harvard Bioscience Inc Transaction History